[XVI Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2023 ECTRIMS Congress (II)]

Overview

Journal Rev Neurol

Specialty Neurology

Date 2024 Jul 8

PMID 38976584

Authors

O Fernandez

X Montalban

E Aguera

Y Aladro

A Alonso

R Arroyo

L Brieva

C Calles

L Costa-Frossard

S Eichau

J M Garcia-Dominguez

M A Hernandez

L Landete

M Llaneza

S Llufriu

J E Meca-Lallana

V Meca-Lallana

E Moral

J M Prieto

Ll Ramio-Torrenta

N Tellez

L Romero-Pinel

A Vilaseca

A Rodriguez-Antiguedad

Affiliations

Soon will be listed here.

Abstract

The XVI Post-ECTRIMS meeting was held in Seville on 20 and 21 October 2023, where expert neurologists in multiple sclerosis (MS) summarised the main new developments presented at the ECTRIMS 2023 congress, which took place in Milan from 11 to 13 October. The aim of this article is to summarise the content presented at the Post-ECTRIMS Meeting, in an article in two parts. This second part covers the health of women and elderly MS patients, new trends in the treatment of cognitive impairment, focusing particularly on meditation, neuroeducation and cognitive rehabilitation, and introduces the concept of fatigability, which has been used to a limited extent in MS. The key role of digitalization and artificial intelligence in the theoretically near future is subject to debate, along with the potential these technologies can offer. The most recent research on the various treatment algorithms and their efficacy and safety in the management of the disease is reviewed. Finally, the most relevant data for cladribine and evobrutinib are presented, as well as future therapeutic strategies currently being investigated.

References

Prosperini L, Haggiag S, Tortorella C, Galgani S, Gasperini C . Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression. Mult Scler. 2020; 27(9):1391-1402. DOI: 10.1177/1352458520964778. View

Alping P, Askling J, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M . Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Ann Neurol. 2020; 87(5):688-699. DOI: 10.1002/ana.25701. View

Roybal K, Williams J, Morsut L, Rupp L, Kolinko I, Choe J . Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell. 2016; 167(2):419-432.e16. PMC: 5072533. DOI: 10.1016/j.cell.2016.09.011. View

Clucas J, Meier P . Roles of RIPK1 as a stress sentinel coordinating cell survival and immunogenic cell death. Nat Rev Mol Cell Biol. 2023; 24(11):835-852. DOI: 10.1038/s41580-023-00623-w. View

Mainguy M, Tillaut H, Degremont A, Le Page E, Mainguy C, Duros S . Assessing the Risk of Relapse Requiring Corticosteroids After In Vitro Fertilization in Women With Multiple Sclerosis. Neurology. 2022; 99(17):e1916-e1925. DOI: 10.1212/WNL.0000000000201027. View

Martin E, Aigrot M, Grenningloh R, Stankoff B, Lubetzki C, Boschert U . Bruton's Tyrosine Kinase Inhibition Promotes Myelin Repair. Brain Plast. 2020; 5(2):123-133. PMC: 7685672. DOI: 10.3233/BPL-200100. View

Fox R, Wiendl H, Wolf C, De Stefano N, Sellner J, Gryb V . A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis. Ann Clin Transl Neurol. 2022; 9(7):977-987. PMC: 9268865. DOI: 10.1002/acn3.51574. View

Otero-Romero S, Lebrun-Frenay C, Reyes S, Amato M, Campins M, Farez M . European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs. Eur J Neurol. 2023; 30(8):2144-2176. DOI: 10.1111/ene.15809. View

Block V, Lizee A, Crabtree-Hartman E, Bevan C, Graves J, Bove R . Continuous daily assessment of multiple sclerosis disability using remote step count monitoring. J Neurol. 2016; 264(2):316-326. PMC: 5292081. DOI: 10.1007/s00415-016-8334-6. View

10.

Ciotti J, Valtcheva M, Cross A . Effects of MS disease-modifying therapies on responses to vaccinations: A review. Mult Scler Relat Disord. 2020; 45:102439. PMC: 7395588. DOI: 10.1016/j.msard.2020.102439. View

11.

Prouskas S, Schoonheim M, Huiskamp M, Steenwijk M, Gehring K, Barkhof F . A randomized trial predicting response to cognitive rehabilitation in multiple sclerosis: Is there a window of opportunity?. Mult Scler. 2022; 28(13):2124-2136. PMC: 9574229. DOI: 10.1177/13524585221103134. View

12.

Tortorella C, Aiello A, Gasperini C, Agrati C, Castilletti C, Ruggieri S . Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies. Neurology. 2021; 98(5):e541-e554. PMC: 8826460. DOI: 10.1212/WNL.0000000000013108. View

13.

Penner I, Paul F . Fatigue as a symptom or comorbidity of neurological diseases. Nat Rev Neurol. 2017; 13(11):662-675. DOI: 10.1038/nrneurol.2017.117. View

14.

Graham E, Bakkensen J, Anderson A, Lancki N, Davidson A, Perez Giraldo G . Inflammatory Activity After Diverse Fertility Treatments: A Multicenter Analysis in the Modern Multiple Sclerosis Treatment Era. Neurol Neuroimmunol Neuroinflamm. 2023; 10(3). PMC: 10018493. DOI: 10.1212/NXI.0000000000200106. View

15.

Chataway J, Schuerer N, Alsanousi A, Chan D, MacManus D, Hunter K . Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet. 2014; 383(9936):2213-21. DOI: 10.1016/S0140-6736(13)62242-4. View

16.

He A, Merkel B, Brown J, Zhovits Ryerson L, Kister I, Malpas C . Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020; 19(4):307-316. DOI: 10.1016/S1474-4422(20)30067-3. View

17.

Graves J, Krysko K, Hua L, Absinta M, Franklin R, Segal B . Ageing and multiple sclerosis. Lancet Neurol. 2022; 22(1):66-77. DOI: 10.1016/S1474-4422(22)00184-3. View

18.

Chappuis M, Rousseau C, Bajeux E, Wiertlewski S, Laplaud D, Le Page E . Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis. J Neurol. 2022; 270(1):413-422. DOI: 10.1007/s00415-022-11341-2. View

19.

Callegari I, Schneider M, Aebischer V, Voortman M, Proschmann U, Ziemssen T . Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis. Ther Adv Neurol Disord. 2023; 16:17562864221150040. PMC: 9896084. DOI: 10.1177/17562864221150040. View

20.

Severijns D, Lamers I, Kerkhofs L, Feys P . Hand grip fatigability in persons with multiple sclerosis according to hand dominance and disease progression. J Rehabil Med. 2014; 47(2):154-60. DOI: 10.2340/16501977-1897. View